Notice2022-08212
Notice of the Commission's Determination Not To Review an Initial Determination Terminating the Investigation on the Basis of Settlement; Termination of the Investigation; Certain Adalimumab, Processes for Manufacturing or Relating to Same, and Products Containing Same
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 18, 2022
Issuing agencies
International Trade Commission
Abstract
Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding administrative law judge's ("ALJ") initial determination ("ID") (Order No. 6) terminating the investigation on the basis of settlement. The investigation is terminated.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 74 (Monday, April 18, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 74 (Monday, April 18, 2022)]
[Notices]
[Page 22940]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-08212]
[[Page 22940]]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1296]
Notice of the Commission's Determination Not To Review an Initial
Determination Terminating the Investigation on the Basis of Settlement;
Termination of the Investigation; Certain Adalimumab, Processes for
Manufacturing or Relating to Same, and Products Containing Same
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined not to review the presiding administrative
law judge's (``ALJ'') initial determination (``ID'') (Order No. 6)
terminating the investigation on the basis of settlement. The
investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Amanda Pitcher Fisherow, Esq., Office
of the General Counsel, U.S. International Trade Commission, 500 E
Street SW, Washington, DC 20436, telephone (202) 205-2737. Copies of
non-confidential documents filed in connection with this investigation
may be viewed on the Commission's electronic docket (EDIS) at <a href="https://edis.usitc.gov">https://edis.usitc.gov</a>. For help accessing EDIS, please email
<a href="/cdn-cgi/l/email-protection#1a5f5e534929527f766a5a6f69736e79347d756c"><span class="__cf_email__" data-cfemail="3570717c66067d5059457540465c41561b525a43">[email protected]</span></a>. General information concerning the Commission may
also be obtained by accessing its internet server at <a href="https://www.usitc.gov">https://www.usitc.gov</a>. Hearing-impaired persons are advised that information on
this matter can be obtained by contacting the Commission's TDD terminal
on (202) 205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on January 31, 2022, based on a complaint filed by AbbVie Inc. of
Chicago, Illinois, AbbVie Biotechnology Ltd of Bermuda, and AbbVie
Operations Singapore Pte. Ltd. of Singapore. 87 FR 4912-13 (Jan. 31,
2022). The complaint, as supplemented, alleged violations of section
337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon
the importation into the United States, the sale of certain adalimumab,
processes for manufacturing or relating to same, and products
containing same by reason of the misappropriation of trade secrets and
tortious interference with contractual relations, the threat or effect
of which is to destroy or substantially injure an industry in the
United States. The complaint, as amended, further alleged that a
domestic industry exists. The notice of investigation named as
respondents Alvotech hf. of Iceland; Alvotech Germany GmbH of Germany;
Alvotech Swiss AG of Zurich, Switzerland; Alvotech USA Inc. of
Arlington, Virginia, and Ivers-Lee AG of Bern, Switzerland. Id. The
Office of Unfair Import Investigations (``OUII'') was also named as a
party to the investigation. Id.
On March 11, 2022, the private parties jointly moved to terminate
the investigation on the basis of settlement. OUII filed a response in
support of the motion. On March 28, 2022, the presiding ALJ issued
Order No. 6, granting the joint motion. The ID found that the parties
complied with Commission Rule 210.21(b). The ID also found that
termination of the investigation will not adversely affect the public
interest. No one petitioned for review of the ID.
The Commission has determined not to review the ID. The
investigation is terminated.
The Commission vote for this determination took place on April 12,
2022.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: April 12, 2022.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2022-08212 Filed 4-15-22; 8:45 am]
BILLING CODE 7020-02-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 18, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.